EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Osimertinib Resistance in EGFR‐Mutated Non–Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies

Junfeng Guo, Qiuyuan Wen, Songqing Fan iD

MedComm · 2026-07 · 7 (7)

DOI: 10.1002/mco2.70823 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 02.07.2026. Verfasst von Junfeng Guo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology The Second Xiangya Hospital Central South University Changsha China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 253 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non–small cell lung cancer (NSCLC) is a leading cause of cancer‐related deaths worldwide, with epidermal growth factor receptor ( EGFR ) mutations being one of the most common actionable genetic alterations. Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor (EGFR‐TKI), has significantly improved the prognosis of patients with EGFR‐mutated NSCLC, but acquired resistance remains a major clinical obstacle limiting its long‐term efficacy. This review summarizes key mechanisms of osimertinib resistance, including both EGFR‐dependent and EGFR‐independent resistance pathways. A major focus is placed on the chromatin remodeler Switch/Sucrose nonfermentable (SWI/SNF) related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily A, member 4 (SMARCA4), which mediates resistance through its interplay with EGFR signaling. Epigenetically, SMARCA4 loss modulates the tumor microenvironment and therapeutic response by triggering a stress‐induced yet functionally impaired nuclear factor erythroid 2‐related factor 2 (NRF2) antioxidant pathway and activating phosphatidylinositol 3‐kinase/protein kinase B (PI3K/AKT) signaling. This cascade not only promotes tumor proliferation and survival but also directly confers resistance to osimertinib. Beyond SMARCA4, this review also discusses bypass pathway activation and further summarizes recent advances in novel targeted agents and combination therapies against osimertinib resistance. Overall, it provides an integrated overview of resistance mechanisms and supports the development of improved precision therapies for EGFR‐mutant NSCLC.

Schlagwörter

Stichwörter der Autor:innen

Osimertinib resistanceSWI/SNF relatedactin dependent regulator of chromatinepidermal growth factor receptor mutation (EGFR)matrix associatedmember 4 (SMARCA4)non–small cell lung cancersubfamily Atherapeutic strategy

Autor:innen und Institutionen

  • Department of Pathology The Second Xiangya Hospital Central South University Changsha China.
  • Hunan Clinical Medical Research Center for Cancer Pathogenic Genes Testing and Diagnosis Changsha China.

ORCID-Profile: Songqing Fan

Zitieren

APA

Guo, J., Wen, Q., & Fan, S. (2026). Osimertinib Resistance in EGFR‐Mutated Non–Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies. MedComm, 7(7). https://doi.org/10.1002/mco2.70823

Vancouver

Guo J, Wen Q, Fan S. Osimertinib Resistance in EGFR‐Mutated Non–Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies. MedComm. 2026;7(7). doi:10.1002/mco2.70823

BibTeX
@article{Guo2026,
  author = {Guo, Junfeng and Wen, Qiuyuan and Fan, Songqing},
  title = {Osimertinib Resistance in EGFR‐Mutated Non–Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {7},
  doi = {10.1002/mco2.70823}
}
Kostenlos starten →